COYA · Healthcare
Costar Group Inc
40/100
Smart-money confidence1 of 3 sources positive
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
53
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$113M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About COSTAR GROUP INC
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as…
Who's behind the signal
Every informed buyer we can see on COYA, across all three feeds.
Hedge funds · 9
Akre Capital Management (Akre)
Increased +8%
Baillie Gifford & Co
Increased +5%
D.E. Shaw & Co
Increased +553%
Gotham Asset Mgmt (Greenblatt)
Increased +243%
Citadel Advisors
Increased +80%
AQR Capital Management
Increased +242%
+3 more in the full breakdown below ↓
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
COSTAR GROUP INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
0
New positions
6
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.5×
% of portfolio
6.8%
Position change
+8%
6.8% of Akre Capital Management's portfolio
Trust weight: 1.4×
% of portfolio
0.6%
Position change
+5%
0.6% of Baillie Gifford & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.2%
Position change
+553%
0.2% of D.E. Shaw & Co's portfolio
Trust weight: 1.1×
% of portfolio
0.1%
Position change
+243%
0.1% of Gotham Asset Mgmt's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+80%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+242%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.4×
% of portfolio
0.3%
Position change
−34%
0.3% of Tiger Global Management's portfolio
Trust weight: 1.2×
% of portfolio
0.0%
Position change
−12%
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−80%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to COSTAR GROUP INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell COSTAR GROUP INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime